Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16. With the stock trading at $10.69 — down nearly 32% year-to-date despite strong fundamentals — Barclays sees an attractive entry point ahead of what it expects to be a meaningful volume and revenue ramp for the rest of 2026.
| Ticker | Firm | Old → New Rating | New Price Target | One-Line Takeaway |
|---|---|---|---|---|
| PHAT | Barclays | Equal Weight → Overweight | $18 | Pullback creates entry ahead of prescription ramp and Q3 profitability target |
The Analyst’s Case
Davidner acknowledges that Q1 prescription trends are “lighter,” but argues the shares offer an attractive entry point ahead of the expected volume and revenue ramp for the remainder of the year. Crucially, Barclays believes weekly prescription data could serve as a positive near-term catalyst, and notes that consensus revenue expectations sit at the midpoint of the company’s own guidance — a setup the firm characterizes as positive for the stock.
Company Snapshot & Recent Performance
Phathom’s sole commercial asset, VOQUEZNA (vonoprazan), is a potassium-competitive acid blocker approved for GERD and H. pylori treatment. Prescription momentum has been consistent: quarterly fills grew from ~127,000 in Q1 2025 to ~273,000 in Q4 2025, pushing cumulative totals past 1.1 million prescriptions. That commercial traction drove Q4 revenue to $57.58 million, up 94.12% year-over-year, while EPS of -$0.08 significantly beat the -$0.42 consensus estimate. Operating expenses fell to $55.87 million from $85.27 million a year earlier, and net cash usage narrowed to roughly $5.2 million in Q4 from ~$14 million in Q3.
Why the Move Matters Now
Management has guided for $320–$345 million in FY 2026 net revenue and expects to reach operating profitability (excluding stock-based compensation) beginning in Q3 2026. Barclays’ $18 target remains below the broader analyst consensus target of $23.50. Guggenheim recently raised its target to $25, maintaining a Buy rating. VOQUEZNA also carries New Chemical Entity exclusivity through May 2032, with generic entry considered unlikely before 2033, providing a long runway for revenue growth.
What It Means for Your Portfolio
The YTD pullback has compressed the valuation at a moment when the operational story remains intact. That said, risks are real: Phathom carries negative stockholders’ equity of -$438.17 million, a $175 million term loan, and RIFA cash hold covenants that begin in October 2026 with a peak obligation of approximately $120 million. Incoming weekly prescription reports will be the clearest signal of whether Q1’s softer start is a temporary pause or a more meaningful slowdown heading into the pivotal back half of 2026.
Top Gaining Stocks
Top Losing Stocks